[1] Novelli MR, Williamson JA, Tomlinson IP, Elia G, Hodg-son SV, Talbot IC, Bodmer WF, Wright NA. Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science, 1996, 272(5265): 1187-1190.
[2] Leroi AM, Koufopanou V, Burt A. Cancer selection. Nat Rev Cancer, 2003, 3(3): 226- 231.
[3] Gatenby RA, Vincent TL. Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther, 2003, 2(9): 919- 927.
[4] Marusyk A, Almendro V, Polyak K. Intra-tumour hetero-geneity: a looking glass for cancer? Nat Rev Cancer, 2012, 12(5): 323-334.
[5] Longo DL. Tumor heterogeneity and personalized medi-cine. N Engl J Med, 2012, 366(10): 956-957.
[6] Shibata D. Cancer. Heterogeneity and tumor history. Science, 2012, 336(6079): 304- 305.
[7] Anderson K, Lutz C, van Delft FW, Bateman CM, Guo YP, Colman SM, Kempski H, Moorman AV, Titley I, Swans-bury J, Kearney L, Enver T, Greaves M. Genetic variegation of clonal architecture and propagating cells in leu-kaemia. Nature, 2011, 469(7330): 356-361.
[8] Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endes-felder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, No-hadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 2012, 366(10): 883-892.
[9] Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell, 2011, 145(1): 30-38.
[10] Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. On-cology, 2001, 61(Suppl. 2): 67-72.
[11] Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD. Comparative lesion sequencing provides insights into tu-mor evolution. Proc Natl Acad Sci USA, 2008, 105(11): 4283-4288.
[12] Ding L, Ellis MJ, Li SQ, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang QY, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du FY, Hawkins AE, O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER. Genome remodeling in a basal-like breast cancer metastasis and xenograft. Nature, 2010, 464(7291): 999-1005.
[13] Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu BJ, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacob-uzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 2010, 467(7319): 1114- 1117.
[14] Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute mye-loid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481(7382): 506-510.
[15] Pietras
